target directory

amantadine ribavirin oseltamivir oseltamivir clinical trial intelligence

Trials are included when the normalized target field matches this target directory. Full protocol, result, eligibility and IP analysis is available inside the premium workspace.

Validated reports

1

Directory type

target

Association rule

normalized field

NCT01227967
Source recordAI-normalized

A Randomized Double-Blind Phase 2 Study Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications

Seasonal influenza is responsible for many hospitalizations and deaths each year, despite effective antiviral treatments. Some individuals have medical conditions such as heart or lung diseases that make them particularly at risk of severe influenza infections that may result in hospitalization or death. Oseltamivir (Tamiflu) is used most often to treat flu, but there are still many hospitalizations, complications, and deaths even with treatment. This study evaluated the use of combination antivirals (amantadine, oseltamivir, and ribavirin) compared to oseltamivir alone in the treatment of influenza in an at-risk population.

AI analysis

Indication: Influenza

Modality: small molecule

Target: Amantadine, Ribavirin, Oseltamivir, Oseltamivir

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Source URL: ClinicalTrials.gov

Source updated: Feb 04, 2019

Ingested: Jun 08, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: Amantadine, Ribavirin, Oseltamivir, Oseltamivir

View original source fields

Condition raw: Influenza

Condition normalized: Influenza

Modality raw: small molecule

Modality normalized: small molecule

Target raw: Amantadine, Ribavirin, Oseltamivir, Oseltamivir

Target normalized: Amantadine, Ribavirin, Oseltamivir, Oseltamivir

Open report